RemeGen Executive and Leadership Team

Jianmin Fang, the Chief Executive Officer at RemeGen, directs the overarching strategic vision for the biopharmaceutical pipeline. Fang architects the long-term research goals, focusing specifically on the advancement of dual-target fusion proteins and antibody-drug conjugates. By aligning scientific discovery with global market needs, the Chief Executive Officer ensures the company maintains a competitive edge in the autoimmune and oncology sectors. Jianmin Fang oversees the integration of advanced technology into drug development processes, driving efficiency across all research stages. This leadership role involves constant collaboration with the board to secure resources for clinical trials and international expansion. Through the prioritization of high-impact therapeutic candidates, the Chief Executive Officer strengthens the market position of the organization. Ultimately, Fang secures the future of the company by fostering a culture of innovation and scientific rigor that addresses critical unmet medical needs worldwide.

Jian Lin, the Executive Director & Chief Executive Officer at RemeGen, manages the corporate governance and operational execution of the business model. Lin drives the implementation of strategic initiatives, ensuring that the development of flagship products like Telitacicept and Disitamab Vedotin remains on schedule. The Executive Director & Chief Executive Officer coordinates cross-departmental efforts to optimize the transition from research to commercialization. Jian Lin monitors the regulatory landscape to ensure compliance while facilitating the expansion of the company footprint across international markets. By balancing fiscal responsibility with aggressive growth targets, the Executive Director & Chief Executive Officer maintains the stability of the organization. This role requires constant interaction with stakeholders to communicate the value of the drug pipeline. Through meticulous oversight of corporate policy, Lin ensures that the company achieves its mission of delivering life-saving treatments to patients globally.

Shaojing Tong, the Chief Financial Officer at RemeGen, directs the financial planning, capital allocation, and fiscal reporting for the entire enterprise. Tong architects the budgetary frameworks that support the intensive research and development requirements of the biopharmaceutical pipeline. The Chief Financial Officer monitors cash flow and investment performance to ensure the company maintains the liquidity necessary for ongoing clinical trials. Shaojing Tong oversees the financial risk management strategies, protecting the organization against market volatility while facilitating sustainable growth. This leadership role involves providing the board with accurate financial insights to guide strategic decision-making regarding future drug development projects. By optimizing the capital structure, the Chief Financial Officer ensures that the company remains well-positioned to fund its ambitious scientific goals. Through rigorous financial oversight, Tong supports the operational efficiency and long-term economic viability of the business in the competitive global pharmaceutical landscape.

Kaisheng Huang, the Chief Operating Officer & Chief Quality Officer at RemeGen, directs the internal manufacturing processes and quality assurance protocols. Huang architects the operational workflows that ensure every drug candidate meets the highest international safety and efficacy standards. The Chief Operating Officer & Chief Quality Officer oversees the supply chain logistics and production facilities, ensuring that the development of complex fusion proteins remains consistent and scalable. Kaisheng Huang monitors the implementation of quality management systems to maintain regulatory compliance across all manufacturing sites. By streamlining operational procedures, the Chief Operating Officer & Chief Quality Officer reduces production bottlenecks and enhances overall output efficiency. This leadership role involves constant collaboration with research teams to ensure that quality standards are integrated into the earliest stages of drug development. Through the maintenance of rigorous quality control, Huang ensures the reliability of the product pipeline and the safety of patients.

Xiaoming Yang, the Chief Marketing Officer at RemeGen, directs the commercial strategy and market positioning for all therapeutic assets. Yang architects the outreach programs that introduce innovative drugs for autoimmune diseases and cancers to healthcare providers and medical institutions. The Chief Marketing Officer analyzes market trends to identify growth opportunities, ensuring that the company effectively communicates the clinical benefits of its antibody-drug conjugates. Xiaoming Yang oversees the development of promotional materials and educational campaigns that support the adoption of new treatments. By building strong relationships with key opinion leaders, the Chief Marketing Officer drives brand awareness and market penetration. This leadership role involves coordinating with sales teams to ensure consistent messaging across diverse geographic regions. Through the execution of data-driven marketing strategies, Yang maximizes the commercial impact of the product portfolio and supports the long-term revenue objectives of the organization.